Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Trames Bio, Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 2 distinct art units. RIGA, MICHAEL ANGELO is the busiest examiner, with 1 pending matter. The examiner assignments are fully distributed, while the art-unit assignments include some concentration.
Counsel should coordinate the scientific terminology and disclosure analysis across the portfolio, but should not assume that the matters will receive identical treatment. Biotechnology and pharmaceutical claims may depend on compounds, biological mechanisms, uses, or experimental support, so each response should identify the specific disputed limitation and its written-description basis. The presence of fewer art units than examiners makes art-unit context useful for grouping issues, while examiner-specific review should control arguments and amendments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RIGA, MICHAEL ANGELO | 1 | 56.2% | +63.0% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
| TIWARI, VYOMA SHUBHAM | 1 | 32.1% | +47.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729329 | EXPRESSION CASSETTES FOR TREATING EPILEPSY AND NEUROPATHIC PAIN | RIGA, MICHAEL ANGELO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022358 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | DEBERRY, REGINA M | 4d overdue |
| 18729329 | EXPRESSION CASSETTES FOR TREATING EPILEPSY AND NEUROPATHIC PAIN | RIGA, MICHAEL ANGELO | — |
| 16925174 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TIWARI, VYOMA SHUBHAM | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729329 | EXPRESSION CASSETTES FOR TREATING EPILEPSY AND NEUROPATHIC PAIN | RIGA, MICHAEL ANGELO | 1634 | §102§103§112Other | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18022358 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | DEBERRY, REGINA M | 1647 | DP | Final Rejection | 4d overdue | Pending | Feb 21, 2023 |
| 16925174 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TIWARI, VYOMA SHUBHAM | 1634 | §103 | Non-Final OA | — | Pending | Jul 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrames Bio, Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Michael Angelo Riga has the most, with 1 of Trames Bio, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
